Pharmaceutical Industry Grows as High-Value Products Drive Corporate Performance
The national pharmaceutical industry continues to face both challenges and growth opportunities alongside the increasing demand for public healthcare services. Amidst market shifts and production cost pressures, pharmaceutical companies are required to innovate, improve operational efficiency, and strengthen manufacturing capacity to maintain sustainable business growth.
In addition to product development, strengthening distribution networks and enhancing production capabilities are vital factors in supporting the competitiveness of pharmaceutical companies in both domestic and regional markets.
PT Pyridam Farma Tbk (IDX: PYFA) recorded positive performance growth in the first quarter of 2026 compared to the same period the previous year. The company booked net revenue of Rp766.53 billion, an 11.8% increase compared to the first quarter of 2025, which stood at Rp685.46 billion.
In line with revenue growth, the company’s gross profit also increased by 6.9% to Rp192.8 billion. This rise was supported by manufacturing efficiencies and increased productivity, which helped offset rising raw material costs and market price pressures.
In terms of profitability, PYFA recorded a 30% growth in EBITDA compared to the same period last year. The EBITDA margin also improved to 9.5%, up from 8.2% in the first quarter of 2025.
The company believes these achievements reflect the effectiveness of its ongoing business transformation strategy. The financial performance improvement was supported by a strengthened pharmaceutical product portfolio, optimisation of distribution networks, and an increasing contribution from its integrated healthcare business lines.
PYFA Director, Sinta Ningsih, stated that the performance at the beginning of the year demonstrates a strengthening business foundation and serves as essential capital to drive growth in subsequent periods.
“In addition to the sustained contribution from our main growth pillar, CDMO services, revenue growth was also driven by the improved performance of several high-licence pharmaceutical products that offer higher value and better margins. Alongside this, the progress of various strategic investments, including the development of Production Line 3 by our subsidiary, provides a positive signal for the Company’s future growth prospects. We are optimistic that our strategy of focusing on high-value product portfolios and strengthening manufacturing capacity will further enhance PYFA’s long-term competitiveness,” said Sinta Ningsih.
To support business growth, the company continues to expand its production capacity. Following the development of Production Line 3 through its subsidiary, PT Ethica Industri Farmasi, PYFA is currently preparing the construction of Production Line 4 and Production Line 5.
The development of these facilities is expected to increase production capacity and strengthen the company’s ability to meet the needs of the evolving national pharmaceutical market.
Moving forward, the Company is optimistic about maintaining its growth momentum through a combination of strategies, including the development of high-licence products, focusing on therapeutic areas with high potential, expanding manufacturing capacity, strengthening healthcare networks, and developing business portfolios in high-growth segments.
These steps are considered crucial to strengthening the company’s position in the pharmaceutical industry while supporting efforts to increase the availability of health products for the Indonesian people.